Amit N Vora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7788816/publications.pdf

Version: 2024-02-01

471509 377865 1,971 41 17 34 citations h-index g-index papers 41 41 41 3438 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	27.0	833
2	Incidence, Predictors, and Outcomes of PermanentÂPacemaker Implantation Following Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2016, 9, 2189-2199.	2.9	271
3	Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population. JAMA Cardiology, 2017, 2, 409.	6.1	110
4	Incidence, Management, and Associated Clinical Outcomes of New-Onset AtrialÂFibrillation Following TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1746-1756.	2.9	84
5	Sex Differences in Platelet Reactivity andÂCardiovascular and Psychological Response to Mental Stress in Patients WithÂStable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 64, 1669-1678.	2.8	78
6	Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction. European Heart Journal, 2016, 37, 2276-2286.	2.2	74
7	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. JAMA Internal Medicine, 2015, 175, 207.	5.1	72
8	An open-Label, 2 \tilde{A} — 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal, 2018, 200, 17-23.	2.7	69
9	Data monitoring committees: Promoting best practices to address emerging challenges. Clinical Trials, 2017, 14, 115-123.	1.6	61
10	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non–ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 513-522.	2.2	42
11	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	3.9	41
12	Firstâ€inâ€human experience with Aortix intraaortic pump. Catheterization and Cardiovascular Interventions, 2019, 93, 428-433.	1.7	29
13	An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. Journal of the American Society of Echocardiography, 2016, 29, 315-322.	2.8	24
14	Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to Endâ€6tage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program. Journal of the American Heart Association, 2017, 6, .	3.7	22
15	Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non–ST-segment elevation acute coronary syndrome. American Heart Journal, 2014, 168, 189-196.e1.	2.7	19
16	Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002477.	3.9	18
17	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation inÂBleeding Rates Following PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 771-779.	2.9	17
18	Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery. JAMA Internal Medicine, 2016, 176, 611.	5.1	17

#	Article	IF	CITATIONS
19	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Tj ETQq1	1 0.78 481 4 rgB	T ‡© verlock
20	Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	10
21	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study, Journal of the American Heart Association, 2016, 5	3.7	9
22	Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 109-116.	2.2	9
23	Bleeding Complications After PCI and the Role of Transradial Access. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 305.	0.9	8
24	Valve-in-Ring Transcatheter Aortic Valve Replacement After Left Ventricular Assist Device Therapy. Annals of Thoracic Surgery, 2020, 109, e163-e165.	1.3	8
25	Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. Journal of Thoracic Disease, 2018, 10, S3595-S3598.	1.4	7
26	Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e009963.	3.9	7
27	Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. Current Cardiology Reports, 2018, 20, 130.	2.9	6
28	Geographic dispersion of TAVR services: Ensuring availability while maintaining quality. American Heart Journal, 2016, 177, 160-162.	2.7	5
29	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology, 2022, 7, 682.	6.1	3
30	Staying in the Shallow End. Circulation: Cardiovascular Interventions, 2021, 14, e010330.	3.9	2
31	Abstract 18699: Negative Predictive Value of Transthoracic Echocardiography for Infective Endocarditis in the Modern Era. Circulation, 2014, 130, .	1.6	2
32	A Company of Equals. Journal of the American College of Cardiology, 2015, 66, 589-591.	2.8	1
33	Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. Structural Heart, 2018, 2, 388-395.	0.6	1
34	Posting Another Win for Intravascular Imaging: Moving Away From Angiography-Only Percutaneous Coronary Intervention Toward a More Comprehensive Approach. Circulation: Cardiovascular Interventions, 2022, 15, e011670.	3.9	1
35	Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. Journal of Thrombosis and Thrombolysis, 2014, 38, 73-77.	2.1	O
36	Same day discharge following transradial PCI in India: Creating value for patients and providers. Indian Heart Journal, 2015, 67, 90-92.	0.5	0

AMIT N VORA

#	Article	IF	CITATIONS
37	Practice Variation in Patients Eligible forÂTriple Therapy. JACC: Clinical Electrophysiology, 2016, 2, 44-46.	3.2	O
38	Rejoinder. Clinical Trials, 2017, 14, 126-127.	1.6	0
39	Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Interventionâ€"Reply. JAMA Cardiology, 2021, 6, 241.	6.1	O
40	For TAVR, Home Is Where the Heart Is. Journal of the American College of Cardiology, 2022, 79, 145-147.	2.8	0
41	Transcatheter Aortic Valve Replacement Optimization Strategies: Cusp Overlap, Commissural Alignment, Sizing, and Positioning. US Cardiology Review, 0, 16 , .	0.5	0